23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec.

Novartis Pharmaceuticals Canada is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance on the public reimbursement of Cosentyx (secukinumab) for the treatment of adults with moderate to severe hidradenitis suppurativa, a chronic, painful and often debilitating inflammatory skin condition.

Read Novartis press release